Clinical trials: Parkinsons Disease (PD)
Parkinson Disease
Survey on PD Patients With Depressive Symptoms
The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings…
- Trial name
- NCT00614575
- Where
- 238 sites in Japan
- Volunteers
- 1,089 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide…
- Trial name
- NCT02169466
- Testing
- BIA 9-1067, Madopar® HBS
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Cognitive Decline in Non-demented PD
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
- Trial name
- NCT01340885
- Testing
- Strattera, Exelon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Oregon Health and Science University
Parkinson's Disease
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
This study is to evaluate the efficacy of a range of preladenant doses compared with placebo in participants with moderate to severe Parkinson's disease (PD) experiencing motor fluctuations and receiving a stable dose of levodopa…
- Trial name
- NCT01294800
- Testing
- Preladenant
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease, Sleep Disorder
Light Therapy for PD - Dose Selection
This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times…
- Conditions
- Parkinson Disease, Sleep Disorder, Fatigue
- Trial name
- NCT04291014
- Testing
- SunRay Light Boxes
- Where
- 25 sites in United States
- Volunteers
- 203 people
- Sponsor
- Massachusetts General Hospital
Parkinson Disease, Depression
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize…
- Trial name
- NCT00297778
- Testing
- Pramipexole
- Where
- 77 sites in Austria, Finland and 11 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Effectiveness and Implementation of the HiBalance Program in Clinical Practice
This effectiveness-implementation study is a part of the larger study BETA-PD (Balance, Elderly, Training and Activity in Parkinson's Disease), which has the long-term goal to reduce the risk of falling in people with Parkinson's…
- Trial name
- BETA-PD (NCT02727478)
- Testing
- HiBalance training program
- Where
- Sweden
- Volunteers
- 117 people
- Sponsor
- Karolinska Institutet
Parkinson Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive…
- Trial name
- NCT04476017
- Testing
- SAGE-718
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson Disease
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the…
- Trial name
- NCT03521635
- Testing
- Pramipexole SR, Pramipexole IR
- Where
- 12 sites in China
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
The study had three distinct parts and is described as follows: Part 1: To evaluate the dose conversion from CD-LD ER taken alone or in combination with CD-LD IR to IPX066 in subjects with advanced PD To evaluate the utility of…
- Trial name
- NCT01411137
- Testing
- IPX066
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease
A Pilot Study of Oxaloacetate in Subjects With Treated PD
The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4…
- Trial name
- NCT01741701
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Early Parkinson Disease (Early PD)
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified…
- Trial name
- NCT00479401
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 95 sites in United States, Argentina and 12 more
- Volunteers
- 539 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa Decarboxylase Inhibitor (DDCI), in patients with…
- Trial name
- NCT01568073
- Testing
- BIA 9-1067, Entacapone, Levodopa
- Where
- Portugal
- Volunteers
- 600 people
- Sponsor
- Bial - Portela C S.A.
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- NCT04995081
- Testing
- Biological/Vaccine: Allogeneic HB-adMSCs
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hope Biosciences Research Foundation